China's IASO Biotherapeutics nets $108m in Series C round

China's IASO Biotherapeutics nets $108m in Series C round

Photo by Louis Reed on Unsplash

Clinical-stage biopharmaceutical firm IASO Biotherapeutics on Thursday announced it has raised $108 million in a Series C round of financing led by asset manager CDH Baifu.